The estimated Net Worth of Philip D Worboys is at least $5.93 Million dollars as of 9 March 2021. Philip Worboys owns over 8,829 units of Theravance Biopharma Inc stock worth over $2,783,800 and over the last 9 years he sold TBPH stock worth over $743,063. In addition, he makes $2,399,620 as Senior Vice President - Research and Translational Science at Theravance Biopharma Inc.
Philip has made over 4 trades of the Theravance Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 8,829 units of TBPH stock worth $176,580 on 9 March 2021.
The largest trade he's ever made was selling 17,103 units of Theravance Biopharma Inc stock on 20 August 2020 worth over $307,854. On average, Philip trades about 1,045 units every 26 days since 2016. As of 9 March 2021 he still owns at least 343,679 units of Theravance Biopharma Inc stock.
You can see the complete history of Philip Worboys stock trades at the bottom of the page.
Dr. Philip D. Worboys Ph.D. serves as Senior Vice President - Research and Translational Science of the Company., serves as Senior Vice President, Translational Science of the Company. Dr. Worboys has served as our Senior Vice President, Translational Science since March 2016, where is he responsible for leading the progression of drug candidates from the discovery stage into human clinical studies, including clinical pharmacology and biomarker development as well as project management. Previously, Dr. Worboys was Vice President, Drug Metabolism and Pharmacokinetics (DMPK) since he joined Theravance Biopharma in October 2014 from Innoviva, where he held the position of Vice President, DMPK since November 2008. Prior to joining Innoviva, he served as Senior Director, DMPK at Roche Bioscience, Inc. since 2005. Dr. Worboys was an Associate Director, DMPK at Pharmacia Corporation from 2001 until its acquisition by Pfizer, Inc. and was Senior Director, DMPK at Pfizer, Inc. from 2003 to 2005. He spent the first part of his career in DMPK, at Merck Sharp & Dohme in Harlow, United Kingdom, and worked in various capacities at Aventis, Unilever and GlaxoSmithKline prior to that. Dr. Worboys obtained his Ph.D. degree in Pharmaceutics from Manchester University, United Kingdom. He holds a B.Sc. degree in Biochemistry from Imperial College of Science, Technology & Medicine at the University of London.
As the Senior Vice President - Research and Translational Science of Theravance Biopharma Inc, the total compensation of Philip Worboys at Theravance Biopharma Inc is $2,399,620. There are 5 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
Philip Worboys is 50, he's been the Senior Vice President - Research and Translational Science of Theravance Biopharma Inc since 2019. There are 20 older and 5 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Philip's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: